Raymond Farkouh
YOU?
Author Swipe
View article: Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines
Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines Open
View article: P-1304. Public Health Impact of Changes to Meningococcal Vaccination Platform in the United States
P-1304. Public Health Impact of Changes to Meningococcal Vaccination Platform in the United States Open
Background In the US, vaccination recommendations for the prevention of Invasive meningococcal disease (IMD) include routine MenACWY vaccination at 11-12 years (y) of age and a booster at 16 y and two doses of MenB vaccine as shared clinic…
View article: P-629. The Health and Economic Impact of the PCV15 and PCV20 Priming Series during the First Year of Life in the US
P-629. The Health and Economic Impact of the PCV15 and PCV20 Priming Series during the First Year of Life in the US Open
Background Two pneumococcal conjugate vaccines, 15- (PCV15) and 20- (PCV20) valent formulations, are currently recommended for US infants in a 3+1 schedule. The first 3 doses are administered during the first year of life (‘priming doses’ …
View article: The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US
The Health and Economic Effects of PCV15 and PCV20 During the First Year of Life in the US Open
(1) Background/Objectives: Two pneumococcal conjugate vaccines, 15-(PCV15) and 20-(PCV20) valent formulations, are routinely recommended for US children in a 3+1 schedule. The first three doses are administered during the first year of lif…
View article: Factors impacting vaccine uptake among adult Medicaid beneficiaries: a systematic literature review
Factors impacting vaccine uptake among adult Medicaid beneficiaries: a systematic literature review Open
Vaccine uptake is suboptimal among adult Medicaid beneficiaries. To evaluate factors affecting vaccine uptake among adult Medicaid beneficiaries and/or affecting healthcare providers who vaccinate adult Medicaid beneficiaries, we conducted…
View article: Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13
Cost-effectiveness and impact on infections and associated antimicrobial resistance of 20-valent pneumococcal conjugate vaccine in US children previously immunized with PCV13 Open
A PCV20 catch-up program could prevent pneumococcal infections, antibiotic prescriptions, and antimicrobial-resistant infections and would be cost-saving in the US.
View article: Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions
Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine Among US Children with Underlying Medical Conditions Open
Use of PCV20 among young children with CMC+ and IC in the USA would reduce the clinical burden of pneumococcal disease and yield overall cost savings from both the US healthcare system and societal perspectives. Higher PCV20 uptake could f…
View article: Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants
Cost-effectiveness of 20-valent pneumococcal conjugate vaccine in US infants Open
Infant vaccination with PCV20 is estimated to further reduce pneumococcal disease and associated healthcare system and societal costs compared to both PCV13 and PCV15.
View article: A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’
A Response to: Letter to the Editor Regarding ‘Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age’ Open
View article: Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States
Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States Open
The addition of pneumococcal conjugate vaccines (PCVs) to the United States (US) national immunization program led to significant reductions in incidence, mortality, and associated sequelae caused by pneumococcal disease (PD) in children a…
View article: Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age
Clinical and Economic Burden of Pneumococcal Disease Due to Serotypes Contained in Current and Investigational Pneumococcal Conjugate Vaccines in Children Under Five Years of Age Open
Despite the success of PCV10 and PCV13 in reducing pneumococcal disease, a substantial clinical and economic burden remains due to serotypes contained in investigational vaccines.
View article: Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges
Public health impact of pneumococcal conjugate vaccination: a review of measurement challenges Open
The true impact of PCVs has been consistently underestimated in published analyses due to multiple measurement challenges. Nearly 100 million adults are estimated to have received PCV13 over the last decade globally, potentially preventing…
View article: Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium
Validation of a Novel Forecasting Method for Estimating the Impact of Switching Pneumococcal Conjugate Programs: Evidence from Belgium Open
The findings from this study suggest that previously published modeling results of PCV13 versus PCV10 in other countries may have underestimated the benefit of PCV13. These results highlight the importance of continually protecting against…
View article: Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children
Twenty-Year Public Health Impact of 7- and 13-Valent Pneumococcal Conjugate Vaccines in US Children Open
Pneumococcal conjugate vaccines (PCVs) have been used in the United States since 2000. To assess the cumulative 20-year effect of PCVs on invasive pneumococcal disease (IPD) incidence among children 282,000 cases of IPD, including ≈16,000 …
View article: 1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age
1404. Twenty-year impact of Pneumococcal Conjugate Vaccines (PCV) on the burden of invasive pneumococcal disease in US children less than 5 years of age Open
Background Clinical trials of PCV7 demonstrate significant reductions in vaccine-type (VT) invasive pneumococcal disease (IPD), clinically diagnosed pneumonia in children less than 5 years of age and VT acute otitis media in children < …
View article: 1384. Conceptual Economic Model Methodology for Infant Pneumococcal Conjugate Vaccine Program and its Impact on Antimicrobial Resistance
1384. Conceptual Economic Model Methodology for Infant Pneumococcal Conjugate Vaccine Program and its Impact on Antimicrobial Resistance Open
Background Antimicrobial resistance (AMR) is a global threat to effective prevention and treatment of an ever-increasing range of infections. Pneumococcal conjugate vaccines (PCV) used in infant national immunization programs have been sho…
View article: Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis
Health and Economic Impact of Routine Pediatric Pneumococcal Immunization Programs in Canada: A Retrospective Analysis Open
View article: Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis
Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis Open
View article: Economic evaluation of meningococcal vaccines: considerations for the future
Economic evaluation of meningococcal vaccines: considerations for the future Open
In 2018, a panel of health economics and meningococcal disease experts convened to review methodologies, frameworks, and decision-making processes for economic evaluations of vaccines, with a focus on evaluation of vaccines targeting invas…
View article: Are Children Normal or Inferior Goods? Evidence from Indonesia’s Financial Crisis of 1997
Are Children Normal or Inferior Goods? Evidence from Indonesia’s Financial Crisis of 1997 Open
The purpose of this dissertation is to provide insight into an individual family's fertility response to a short term financial shock. As economies develop, the number of children born in a household decreases at both the inter and intra-c…
View article: Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’”
Comment on Gomez et. al. “Response to article by Wasserman et. al. (2018) ‘Modelling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico’” Open
In a recent Letter, Gomez et. al. provided a critique of our original analysis estimating the clinical and economic impact of switching from the 13-valent (PCV13) to the 10-valent (PCV10) pneumococcal conjugate vaccine in Mexico. This comm…
View article: Estimating the Vaccine Effectiveness Against Serotype 3 for the 13-Valent Pneumococcal Conjugate Vaccine: A Dynamic Modeling Approach
Estimating the Vaccine Effectiveness Against Serotype 3 for the 13-Valent Pneumococcal Conjugate Vaccine: A Dynamic Modeling Approach Open
Background: The 13-valent pneumococcal conjugate vaccine (PCV13) is the only PCV licensed to protect against serotype 3 in children. However, conflicting estimates exist of PCV13's direct and indirect protection vaccine effectiveness (VE) …
View article: Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria
Cost-Effectiveness of the Pneumococcal Conjugate Vaccine (10- or 13-Valent) Versus No Vaccination for a National Immunization Program in Tunisia or Algeria Open
Pfizer.
View article: Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium
Re-Analysis of Modeling a Switch from a 13-Valent to 10-Valent Pneumococcal Conjugate Vaccine in Canada: Leveraging Real-World Experience from Belgium Open
View article: Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada”
Response to McGirr et al.'s Comment on “Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada” Open
View article: 1428. Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination
1428. Modeling Reductions in Antibiotic Prescriptions due to Otitis Media in Canada as a Result of Pneumococcal Conjugate Vaccination Open
BACKGROUND: Vaccines are an important factor in combating the growing global health issue of antimicrobial resistance. Pneumococcal conjugate vaccines (PCVs) have substantially reduced the burden of otitis media (OM) caused by S. pneumonia…
View article: PIN82 - IN SMALL DOSES: MISSING THE BOOSTER DOSE IN A REDUCED PNEUMOCOCCAL CONJUGATE VACCINATION SCHEDULE
PIN82 - IN SMALL DOSES: MISSING THE BOOSTER DOSE IN A REDUCED PNEUMOCOCCAL CONJUGATE VACCINATION SCHEDULE Open
View article: Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico
Modeling the sustained use of the 13-valent pneumococcal conjugate vaccine compared to switching to the 10-valent vaccine in Mexico Open
The PCV program in Mexico has provided a significant return on investment. Sustained PCV13 use was estimated to provide the greatest healthcare and economic impact in Mexico. Changes to the pneumococcal vaccination program could result in …
View article: Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China
Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China Open
Initiation of a PCV13 NIP in China incurs large upfront costs but is good value for money, and is likely to prevent substantial cases of disease among children and non-vaccinated individuals.
View article: Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK
Dynamic transmission modelling to address infant pneumococcal conjugate vaccine schedule modifications in the UK Open
The 13-valent pneumococcal conjugate vaccine (PCV) has been part of routine immunisation in a 2 + 1 schedule (two primary infant doses and one booster during the second year of life) in the UK since 2010. Recently, the UK's Joint Committee…